Slingshot members are tracking this event:

AbbVie (ABBV) Phase 3 EXPEDITION-1 Results Evaluating Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection With Genotypes 1,2,4,5 or 6 and Compensated Cirrhosis

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 20, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3, Expedition-1, Glecaprevir, Pibrentasvir, Chronic Hcv Infection, Compensated Cirrhosis, International Liver Congress